RBC Capital Raises Price Target for Addus HomeCare to $134, Analyst Maintains "Outperform" Rating
PorAinvest
viernes, 22 de agosto de 2025, 9:20 pm ET1 min de lectura
ADUS--
Barclays has raised its target to $109, while TD Cowen has increased its target to $139. The average analyst target price for ADUS stands at $140.82, indicating a potential 23.33% upside from the current price of $114.18 [1].
Addus HomeCare Corporation provides a range of home care services, including personal care, hospice care, and home health services. These segments cater to various patient needs, from non-medical assistance with activities of daily living to palliative care and skilled nursing services [2].
The latest price target adjustment by RBC Capital Markets underscores the analyst community's optimism regarding ADUS's growth potential. As the demand for home care services continues to rise, driven by an aging population and increased healthcare needs, companies like Addus HomeCare are well-positioned to benefit.
Investors should closely monitor ADUS's financial performance and any updates from the company or analysts to gauge the stock's future prospects. Given the current analyst consensus and price targets, ADUS presents an intriguing opportunity for investors seeking exposure to the home care sector.
References:
[1] https://www.marketscreener.com/news/addus-homecare-insider-sold-shares-worth-2-873-851-according-to-a-recent-sec-filing-ce7c50dad88ff52c
[2] https://www.marketbeat.com/ratings/by-issuer/royal-bank-of-canada-stock-recommendations/
RBC Capital has raised its price target for Addus HomeCare (ADUS) to $134, maintaining its "Outperform" rating. The stock has seen several analyst actions in recent months, with Barclays raising its target to $109 and TD Cowen increasing its target to $139. The average analyst target price is $140.82, indicating a 23.33% upside from the current price of $114.18.
RBC Capital Markets has recently updated its price target for Addus HomeCare Corporation (ADUS), raising it to $134. The investment bank maintains its "Outperform" rating for the stock, reflecting a positive outlook on the company's financial prospects. This move comes amidst a flurry of analyst actions in recent months, with Barclays and TD Cowen also adjusting their price targets for ADUS.Barclays has raised its target to $109, while TD Cowen has increased its target to $139. The average analyst target price for ADUS stands at $140.82, indicating a potential 23.33% upside from the current price of $114.18 [1].
Addus HomeCare Corporation provides a range of home care services, including personal care, hospice care, and home health services. These segments cater to various patient needs, from non-medical assistance with activities of daily living to palliative care and skilled nursing services [2].
The latest price target adjustment by RBC Capital Markets underscores the analyst community's optimism regarding ADUS's growth potential. As the demand for home care services continues to rise, driven by an aging population and increased healthcare needs, companies like Addus HomeCare are well-positioned to benefit.
Investors should closely monitor ADUS's financial performance and any updates from the company or analysts to gauge the stock's future prospects. Given the current analyst consensus and price targets, ADUS presents an intriguing opportunity for investors seeking exposure to the home care sector.
References:
[1] https://www.marketscreener.com/news/addus-homecare-insider-sold-shares-worth-2-873-851-according-to-a-recent-sec-filing-ce7c50dad88ff52c
[2] https://www.marketbeat.com/ratings/by-issuer/royal-bank-of-canada-stock-recommendations/
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios